Loading stock data…
$18.96+0.36 (+1.96%)
Yarrow Bioscience, Inc.
Yarrow Bioscience Inc in the Healthcare sector is trading at $18.96 with a market capitalization of $78M. Wall Street consensus targets $57.00 (2 analysts), implying a +200.6% move over the next 12 months. The stock is currently near its 52-week low of $16.05, remaining 12.0% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: RSI 22 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q2 2025 |
|---|---|---|---|---|
| Total Revenue | $97,000 | $0 | $0↓ | $69,000 |
| Gross Profit | — | — | — | — |
| Operating Income | -$3.10M↓ | -$2.86M↓ | -$994,000↑ | -$7.54M |
| Net Income | -$3.01M↓ | -$2.75M↑ | -$70.99M↓ | -$5.75M |
Yarrow Bioscience, Inc. operates as a clinical-stage biotechnology company that engages in developing transformative therapies for autoimmune thyroid diseases. The company's candidate, YB-101, is a humanized monoclonal antibody targeting the thyroid-...